In this article, we discuss the 5 best biotech stocks to buy according to Mark Lampert. If you want to read our detailed analysis of Lampert’s Biotechnology Value Fund, go directly to the 10 Best Biotech Stocks to Buy According to Mark Lampert.
5. Kymera Therapeutics, Inc. (NASDAQ:KYMR)
Biotechnology Value Fund’s Stake Value: $127,587,000
Percent of Biotechnology Value Fund’s 13F Portfolio: 4.78%
Number of Hedge Fund Holders: 21
Leah Rush Cann of Brookline sees potential in drug development at Kymera Therapeutics, Inc. (NASDAQ:KYMR) and expects the company to launch its first drugs by 2028. Recently, the firm initiated its coverage of the company with a Buy rating and an $88 price target.
Jeremy Green’s Redmile Group is the second-largest shareholder of Kymera Therapeutics, Inc. (NASDAQ:KYMR), owning over 2.5 million shares in the company. In Q2, 21 hedge funds tracked by Insider Monkey reported having stakes in the company, valued at $448.8 million. In the previous quarter, 16 hedge funds owned stakes in the company, highlighting a positive hedge fund sentiment.
BVF owns over 2.6 million shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR) in Q2, valued at $127.5 million. The company represents 4.78% of the hedge fund’s 13F portfolio.
4. Merus N.V. (NASDAQ:MRUS)
Biotechnology Value Fund’s Stake Value: $153,496,000
Percent of Biotechnology Value Fund’s 13F Portfolio: 5.75%
Number of Hedge Fund Holders: 23
Merus N.V. (NASDAQ:MRUS), a Dutch biotechnology company, stands fourth on our list of the best biotech stocks to buy according to Mark Lampert. In Q2, BVF did not make any changes to its position in the company and holds over 7.2 million shares, valued at over $153.4 million. The company represents 5.75% of the hedge fund’s 13F portfolio.
In Q2, Merus N.V. (NASDAQ:MRUS) reported revenue of $12.38 million, showcasing a 103% year-over-year growth. The shares of the company rose 31% on October 7, when the company’s drug, MCLA-158, showed shrinkage of tumors in patients with neck and head cancer. Merus N.V. (NASDAQ:MRUS) gained 122.2% in the past year. This October, Citigroup lifted its price target on Merus N.V. (NASDAQ:MRUS) to $38, with a Buy rating on the shares.
As of Q2 2021, 23 hedge funds tracked by Insider Monkey were bullish on Merus N.V. (NASDAQ:MRUS), the same as in the previous quarter. The total worth of these stakes is $308.7 million.
3. Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Biotechnology Value Fund’s Stake Value: $168,484,000
Percent of Biotechnology Value Fund’s 13F Portfolio: 6.31%
Number of Hedge Fund Holders: 27
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) presented a positive hedge fund sentiment in Q2, as 27 hedge funds in Insider Monkey database were bullish on the company, compared with 20 in the previous quarter. The total value of these stakes is $723.5 million. Consonance Capital Management is one of the largest shareholders of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) in Q2, with shares worth $154.6 million. The company stands third on our list of the best biotech stocks to buy according to Mark Lampert.
In Q2, BVF holds over 3.7 million shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX), valued at $168.4 million. The company accounts for 6.31% of the hedge fund’s 13F portfolio.
2. Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Biotechnology Value Fund’s Stake Value: $186,389,000
Percent of Biotechnology Value Fund’s 13F Portfolio: 6.98%
Number of Hedge Fund Holders: 17
On October 20, shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) surged 15.6% as Michael Yee of Jefferies Financial issued a Buy rating on the stock with a $55 price target. The analyst appreciated the positive results from the company’s Elacestrant, a selective estrogen receptor degrader (SERD), which showed fewer side effects in its Phase 2 studies.
It is the third-largest holding of Biotechnology Value Fund as of Q2. The hedge fund did not make any changes to its position in the company and holds over 6.6 million shares, worth $186.3 million.
Of the 873 hedge funds tracked by Insider Monkey, 17 hedge funds have positions in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) in Q2, compared with 19 in the previous quarter. The total value of these stakes is $624.3 million.
1. argenx SE (NASDAQ:ARGX)
Biotechnology Value Fund’s Stake Value: $196,058,000
Percent of Biotechnology Value Fund’s 13F Portfolio: 7.34%
Number of Hedge Fund Holders: 27
argenx SE (NASDAQ:ARGX) is a Dutch biotechnology company aimed at developing antibody-based therapies for severe autoimmune diseases and cancer.
In Q2 2021, the Biotechnology Value Fund increased its position in argenx SE (NASDAQ:ARGX) by 111% and now holds 651,204 shares in the company, valued at over $196 million. The company represents 7.34% of the hedge fund’s 13F portfolio.
Recently, Jefferies initiated its coverage on argenx SE (NASDAQ:ARGX) with a Buy rating and a $362 price target. As of Q2 2021, 27 hedge funds tracked by Insider Monkey reported having stakes in argenx SE (NASDAQ:ARGX), the same as in the previous quarter. The total value of these stakes is $1.45 billion.
Artisan Partners mentioned argenx SE (NASDAQ:ARGX) in its Q2 2021 investor letter. Here is what the firm has to say:
“Argenx is a Dutch biotechnology company developing antibodybased therapies for autoimmune diseases and cancer. Commercial preparations are underway for the company’s FcRn drug efgartigimod, which is used to treat patients with severe autoimmune diseases. Discussions with health insurance payers have been positive, and the manufacturing/supply chain is well-positioned. Argenx appears to be not only first-in-class (a first mover) but also the best-inclass asset in a high value and competitive field of FcRn drugs. First-inclass drugs typically take the majority of market share, and with a best-in-class profile, Argenx could solidify a dominate market position.”
You can also take a look at 12 Best Large-cap Biotech Stocks To Buy Now and 10 Best Biotech Stocks To Invest In
